{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T04:59:43Z","timestamp":1777093183318,"version":"3.51.4"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T00:00:00Z","timestamp":1534982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T00:00:00Z","timestamp":1534982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jsm.jsexmed.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Following the results of the EMPA-REG Outcome trial, we hypothesized that empagliflozin, a highly potent and specific sodium\/glucose cotransporteur 2 inhibitor, could improve type 2 diabetes mellitus (T2DM)-associated erectile dysfunction (ED), a highly prevalent complication of T2DM, very often coexisting with cardiovascular complications and considered as a prognostic factor of cardiovascular disease in men with diabetes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To investigate the effects of chronic treatment with empagliflozin on ED in a T2DM rat model in the presence or absence of sildenafil.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Male Goto-Kakizaki (GK), a model of T2DM, and age-matched Wistar rats received placebo or empagliflozin treatment at 25.3 \u00b1 0.9 mg\/kg\/d for 4 weeks. Then, the in\u00a0vivo effect of empagliflozin on erectile function was assessed by electrical stimulation of the cavernous nerve at different frequencies under anesthesia in the presence or absence of acute intravenous injection of sildenafil. Endothelium-dependent, -independent, and nitrergic relaxations of cavernosal strips from the rats were studied.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures<\/jats:title>\n                  <jats:p>Body weight, food consumption, metabolic parameters, plasma inflammation biomarkers, and in\u00a0vivo erectile responses elicited by electrical stimulation of the cavernous nerve in empagliflozin-treated and untreated GK rats and control Wistar rats were assessed and followed by concentration or frequency response curves to endothelium-dependent, -independent, and nitrergic relaxations of cavernosal strips from these rats.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Chronic empagliflozin followed by acute sildenafil significantly improved erectile responses in adult GK rats (n\u00a0= 12\u201315\/group). Ratios of intracavernous pressure and area under the curve\/mean arterial pressure during the electrical stimulation were significantly increased in empagliflozin-treated vs untreated GK rats. Nitrergic relaxations of cavernosal strips from GK rats were significantly increased with empagliflozin compared with placebo. Moreover, the effect of sildenafil on erectile function was not altered by empagliflozin treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Implications<\/jats:title>\n                  <jats:p>Empagliflozin may benefit T2DM patient with ED.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Strengths &amp; Limitations<\/jats:title>\n                  <jats:p>The mechanism(s) by which empagliflozin shows favorable effect on erectile function in GK rats needs to be further elucidated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Empagliflozin shows favorable effect on erectile function in diabetic GK rats mediated by an improvement of nitrergic relaxation of erectile tissue. Whether this favorable effect on ED in the experimental context of T2DM is due to better glycemic control or to another effect of empagliflozin deserves further investigation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1016\/j.jsxm.2018.07.002","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T11:01:47Z","timestamp":1535022107000},"page":"1224-1234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["The Favorable Effect of Empagliflozin on Erectile Function in an Experimental Model of Type 2 Diabetes"],"prefix":"10.1093","volume":"15","author":[{"given":"Rana","family":"Assaly","sequence":"first","affiliation":[{"name":"Pelvipharm , Montigny-le-Bretonneux , France"},{"name":"UMR1179 \u00a0 , Montigny-le-Bretonneux , France"},{"name":"Universit\u00e9 Versailles Saint Quentin en Yvelines \u00a0 , Montigny-le-Bretonneux , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Gorny","sequence":"additional","affiliation":[{"name":"Pelvipharm , Montigny-le-Bretonneux , France"},{"name":"UMR1179 \u00a0 , Montigny-le-Bretonneux , France"},{"name":"Universit\u00e9 Versailles Saint Quentin en Yvelines \u00a0 , Montigny-le-Bretonneux , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Compagnie","sequence":"additional","affiliation":[{"name":"Pelvipharm , Montigny-le-Bretonneux , France"},{"name":"UMR1179 \u00a0 , Montigny-le-Bretonneux , France"},{"name":"Universit\u00e9 Versailles Saint Quentin en Yvelines \u00a0 , Montigny-le-Bretonneux , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Mayoux","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma \u00a0 , Biberach an der Riss , Germany"},{"name":"Cardiometabolic Diseases Research \u00a0 , Biberach an der Riss , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Bernabe","sequence":"additional","affiliation":[{"name":"Pelvipharm , Montigny-le-Bretonneux , France"},{"name":"UMR1179 \u00a0 , Montigny-le-Bretonneux , France"},{"name":"Universit\u00e9 Versailles Saint Quentin en Yvelines \u00a0 , Montigny-le-Bretonneux , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Alexandre","sequence":"additional","affiliation":[{"name":"Pelvipharm , Montigny-le-Bretonneux , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Giuliano","sequence":"additional","affiliation":[{"name":"Pelvipharm , Montigny-le-Bretonneux , France"},{"name":"UMR1179 \u00a0 , Montigny-le-Bretonneux , France"},{"name":"Universit\u00e9 Versailles Saint Quentin en Yvelines \u00a0 , Montigny-le-Bretonneux , France"},{"name":"AP-HP, Neuro-Uro-Andrology \u00a0 \u00a0 , Garches , France"},{"name":"Department of Physical Medicine and Rehabilitation \u00a0 \u00a0 , Garches , France"},{"name":"Raymond Poincar\u00e9 Hospital \u00a0 \u00a0 , Garches , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Behr-Roussel","sequence":"additional","affiliation":[{"name":"Pelvipharm , Montigny-le-Bretonneux , France"},{"name":"UMR1179 \u00a0 , Montigny-le-Bretonneux , France"},{"name":"Universit\u00e9 Versailles Saint Quentin en Yvelines \u00a0 , Montigny-le-Bretonneux , France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,8,23]]},"reference":[{"key":"2023012309362302700_bib1","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.urology.2004.08.059","article-title":"Prevalence of erectile dysfunction among 7689 patients with diabetes or hypertension, or both","volume":"64","author":"Giuliano","year":"2004","journal-title":"Urology"},{"key":"2023012309362302700_bib2","first-page":"1232","article-title":"Erectile dysfunction in diabetes mellitus","volume":"6","author":"Malavige","year":"2009","journal-title":"J\u00a0Sex Med"},{"key":"2023012309362302700_bib3","first-page":"1608","article-title":"Cardiovascular aspects of sexual medicine","volume":"7","author":"Jackson","year":"2010","journal-title":"J\u00a0Sex Med"},{"key":"2023012309362302700_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ahj.2012.04.006","article-title":"Prognostic utility of erectile dysfunction for cardiovascular disease in younger men and those with diabetes","volume":"164","author":"Miner","year":"2012","journal-title":"Am Heart J"},{"key":"2023012309362302700_bib5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/sj.ijir.3901494","article-title":"Endothelial dysfunction in diabetic erectile dysfunction","volume":"19","author":"Musicki","year":"2007","journal-title":"Int J Impot Res"},{"key":"2023012309362302700_bib6","first-page":"2233","article-title":"Basic science evidence for the link between erectile dysfunction and cardiometabolic dysfunction","volume":"12","author":"Musicki","year":"2015","journal-title":"J\u00a0Sex Med"},{"key":"2023012309362302700_bib7","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.eururo.2010.02.020","article-title":"Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation","volume":"57","author":"Hatzimouratidis","year":"2010","journal-title":"Eur Urol"},{"key":"2023012309362302700_bib8","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1073\/pnas.052712499","article-title":"Akt-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erection","volume":"99","author":"Hurt","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023012309362302700_bib9","first-page":"758","article-title":"Diabetes exacerbates the functional deficiency of NO\/cGMP pathway associated with erectile dysfunction in human corpus cavernosum and penile arteries","volume":"7","author":"Angulo","year":"2010","journal-title":"J\u00a0Sex Med"},{"key":"2023012309362302700_bib10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1210\/jc.2009-0473","article-title":"Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus","volume":"95","author":"Nair","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"2023012309362302700_bib11","doi-asserted-by":"crossref","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice","volume":"306","author":"Vallon","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"2023012309362302700_bib12","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.hlc.2014.05.007","article-title":"New treatments for type 2 diabetes: cardiovascular protection beyond glucose lowering?","volume":"23","author":"Jayawardene","year":"2014","journal-title":"Heart Lung Circ"},{"key":"2023012309362302700_bib13","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"2023012309362302700_bib14","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"2023012309362302700_bib15","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1161\/CIRCULATIONAHA.105.563213","article-title":"Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms","volume":"113","author":"Kim","year":"2006","journal-title":"Circulation"},{"key":"2023012309362302700_bib16","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1017\/S1462399411001979","article-title":"Diabetic neuropathy and heart failure: role of neuropeptides","volume":"13","author":"Ejaz","year":"2011","journal-title":"Expert Rev Mol Med"},{"key":"2023012309362302700_bib17","doi-asserted-by":"crossref","first-page":"R108","DOI":"10.1152\/ajpregu.00033.2013","article-title":"Bladder and erectile dysfunctions in the type 2 diabetic Goto-Kakizaki rat","volume":"306","author":"Oger-Roussel","year":"2014","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2023012309362302700_bib18","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0306-3623(88)90077-8","article-title":"Metabolic changes induced by urethane-anesthesia in rats","volume":"19","author":"Sanchez-Pozo","year":"1988","journal-title":"Gen Pharmacol"},{"key":"2023012309362302700_bib19","first-page":"271","article-title":"Urethane-induced hyperglycemia","volume":"21","author":"Wang","year":"2000","journal-title":"Acta Pharmacol Sin"},{"key":"2023012309362302700_bib20","first-page":"519","article-title":"Antierectile role of the\u00a0sympathetic nervous system in rats","volume":"150","author":"Giuliano","year":"1993","journal-title":"J\u00a0Urol"},{"key":"2023012309362302700_bib21","first-page":"950","article-title":"Low intensity extracorporeal shock wave therapy improves erectile function in a model of type II diabetes independently of NO\/cGMP pathway","volume":"196","author":"Assaly-Kaddoum","year":"2016","journal-title":"J\u00a0Urol"},{"key":"2023012309362302700_bib22","first-page":"453","article-title":"SGLT-2 inhibitors and their potential in the treatment of diabetes","volume":"6","author":"Rosenwasser","year":"2013","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2023012309362302700_bib23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2147\/DMSO.S58786","article-title":"Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet","volume":"7","author":"Vickers","year":"2014","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2023012309362302700_bib24","doi-asserted-by":"crossref","first-page":"F317","DOI":"10.1152\/ajprenal.00145.2014","article-title":"The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob\/ob type 2 diabetic mice with and without hypertension","volume":"307","author":"Gembardt","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"2023012309362302700_bib25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijcard.2016.02.134","article-title":"Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: a comprehensive review of clinical and preclinical studies","volume":"212","author":"Ghosh","year":"2016","journal-title":"Int J Cardiol"},{"issue":"Suppl","key":"2023012309362302700_bib26","first-page":"262","article-title":"Type 1 and type 2 diabetic-erectile dysfunction: same diagnosis (ICD-9), different disease?","volume":"6","author":"Chitaley","year":"2009","journal-title":"J\u00a0Sex Med"},{"key":"2023012309362302700_bib27","first-page":"3620","article-title":"Erectile dysfunction in young non-obese type II diabetic Goto-Kakizaki rats is associated with decreased eNOS phosphorylation at Ser1177","volume":"7","author":"Carneiro","year":"2010","journal-title":"J\u00a0Sex Med"},{"key":"2023012309362302700_bib28","first-page":"916","article-title":"Review type 2 diabetes mellitus and erectile dysfunction","volume":"6","author":"Hidalgo-Tamola","year":"2009","journal-title":"J\u00a0Sex Med"},{"key":"2023012309362302700_bib29","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0025-7125(05)70211-X","article-title":"C-reactive protein, inflammation, and coronary risk","volume":"84","author":"Morrow","year":"2000","journal-title":"Med Clin North Am"},{"key":"2023012309362302700_bib30","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1681\/ASN.2007091048","article-title":"The role of inflammatory cytokines in diabetic nephropathy","volume":"19","author":"Navarro-Gonzalez","year":"2008","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"2023012309362302700_bib31","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1096\/fj.03-1476fje","article-title":"A\u00a0central role for inflammation in the pathogenesis of diabetic retinopathy","volume":"18","author":"Joussen","year":"2004","journal-title":"FASEB J"},{"key":"2023012309362302700_bib32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0272-6386(03)00408-6","article-title":"Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus","volume":"42","author":"Navarro","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"2023012309362302700_bib33","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1016\/j.lfs.2004.09.038","article-title":"Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki rats","volume":"76","author":"Ueta","year":"2005","journal-title":"Life Sci"},{"key":"2023012309362302700_bib34","first-page":"590","article-title":"Nitrergic function is lost but endothelial function is preserved in the corpus cavernosum and penile resistance arteries of men after radical prostatectomy","volume":"12","author":"Martinez-Salamanca","year":"2015","journal-title":"J\u00a0Sex Med"},{"key":"2023012309362302700_bib35","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2174\/156652412802480970","article-title":"Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db\/db mice","volume":"12","author":"Chen","year":"2012","journal-title":"Curr Mol Med"},{"key":"2023012309362302700_bib36","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ejphar.2013.05.014","article-title":"Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice","volume":"715","author":"Tahara","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"2023012309362302700_bib37","doi-asserted-by":"crossref","first-page":"e100777","DOI":"10.1371\/journal.pone.0100777","article-title":"Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice","volume":"9","author":"Terami","year":"2014","journal-title":"PLoS One"},{"key":"2023012309362302700_bib38","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1172\/JCI25102","article-title":"Inflammation, stress, and diabetes","volume":"115","author":"Wellen","year":"2005","journal-title":"J\u00a0Clin Invest"},{"key":"2023012309362302700_bib39","doi-asserted-by":"crossref","first-page":"812","DOI":"10.2337\/diabetes.52.3.812","article-title":"Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)\u2013Potsdam Study","volume":"52","author":"Spranger","year":"2003","journal-title":"Diabetes"},{"key":"2023012309362302700_bib40","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.metabol.2004.02.007","article-title":"Serum tumor necrosis factor-alpha levels and components of the metabolic syndrome in obese adolescents","volume":"53","author":"Moon","year":"2004","journal-title":"Metabolism"},{"key":"2023012309362302700_bib41","first-page":"335","article-title":"Role of oxidative stress in the pathophysiological mechanism of erectile dysfunction","volume":"27","author":"Agarwal","year":"2006","journal-title":"J\u00a0Androl"},{"key":"2023012309362302700_bib42","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1016\/j.lfs.2005.01.033","article-title":"Oxidative stress\u2014mediated alterations in glucose dynamics in a genetic animal model of type II diabetes","volume":"77","author":"Bitar","year":"2005","journal-title":"Life Sci"},{"key":"2023012309362302700_bib43","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2337\/diabetes.48.4.927","article-title":"Hyperglycemia causes oxidative stress in pancreatic beta-cells of GK rats, a model of type 2 diabetes","volume":"48","author":"Ihara","year":"1999","journal-title":"Diabetes"},{"key":"2023012309362302700_bib44","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1017\/S0007114511000493","article-title":"Mitochondrial dysfunction in the liver of type 2 diabetic Goto-Kakizaki rats: improvement by a combination of nutrients","volume":"106","author":"Hao","year":"2011","journal-title":"Br J Nutr"},{"key":"2023012309362302700_bib45","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/dmrr.2407","article-title":"Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis","volume":"29","author":"Maeda","year":"2013","journal-title":"Diabetes Metab Res Rev"},{"key":"2023012309362302700_bib46","doi-asserted-by":"crossref","first-page":"542042","DOI":"10.1155\/2012\/542042","article-title":"Sodium-glucose cotransporter inhibition prevents oxidative stress in the kidney of diabetic rats","volume":"2012","author":"Osorio","year":"2012","journal-title":"Oxid Med Cell Longev"},{"issue":"Suppl","key":"2023012309362302700_bib47","first-page":"353","article-title":"Mechanisms of penile fibrosis","volume":"6","author":"Gonzalez-Cadavid","year":"2009","journal-title":"J\u00a0Sex Med"},{"key":"2023012309362302700_bib48","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1111\/j.1464-410X.2008.08251.x","article-title":"Early onset of fibrosis within the arterial media in a rat model of type 2 diabetes mellitus with erectile dysfunction","volume":"103","author":"Kovanecz","year":"2009","journal-title":"BJU Int"},{"key":"2023012309362302700_bib49","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/2042018814544153","article-title":"Renal effects of dapagliflozin in patients with type 2 diabetes","volume":"5","author":"Thomas","year":"2014","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2023012309362302700_bib50","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","article-title":"Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice","volume":"13","author":"Lin","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"2023012309362302700_bib51","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG outcome trial: a \u201cthrifty substrate\u201d hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609518310622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609518310622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/15\/9\/1224\/48590357\/jsm_15_9_1224.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/15\/9\/1224\/48590357\/jsm_15_9_1224.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T10:03:09Z","timestamp":1674468189000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/15\/9\/1224\/6980478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,23]]},"references-count":51,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,8,23]]},"published-print":{"date-parts":[[2018,9,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.jsxm.2018.07.002","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2018,9]]},"published":{"date-parts":[[2018,8,23]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Favorable Effect of Empagliflozin on Erectile Function in an Experimental Model of Type 2 Diabetes","name":"articletitle","label":"Article Title"},{"value":"The Journal of Sexual Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsxm.2018.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}